about
Role of antiviral therapy in the natural history of hepatitis B virus-related chronic liver diseaseDevelopment and Validation of a New Prognostic System for Patients with Hepatocellular CarcinomaLet-7c down-regulation in Helicobacter pylori-related gastric carcinogenesis.Gastrin: from pathophysiology to cancer prevention and treatment.Sorafenib use in the transplant setting.Dropout rate from the liver transplant waiting list because of hepatocellular carcinoma progression in hepatitis C virus-infected patients treated with direct-acting antivirals.PD-L1 overexpression in ampulla of Vater carcinoma and its pre-invasive lesions.Association of abnormal plasma bilirubin with aggressive hepatocellular carcinoma phenotype.Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon.Years of life that could be saved from prevention of hepatocellular carcinoma.Utility of Tumor Burden Score to Stratify Prognosis of Patients with Hepatocellular Cancer: Results of 4759 Cases from ITA.LI.CA Study Group.Patients with advanced hepatocellular carcinoma need a personalized management: A lesson from clinical practice.Focus on histological abnormalities of intrahepatic vasculature in chronic viral hepatitis.When and how should we perform a biopsy for HCC in patients with liver cirrhosis in 2018? A review.Digital liver biopsy: Bio-imaging of fatty liver for translational and clinical research.Capecitabine in advanced hepatocellular carcinoma.HCV clearance by direct antiviral therapy and occurrence/recurrence of hepatocellular carcinoma: A "true-or-false game".The critical issue of restaging patients with hepatocellular carcinomaOLGA Gastritis Staging for the Prediction of Gastric Cancer Risk: A Long-term Follow-up Study of 7436 PatientsmiR-224 Is Significantly Upregulated and Targets Caspase-3 and Caspase-7 During Colorectal CarcinogenesisLong term results of down-staging and liver transplantation for patients with hepatocellular carcinoma beyond the conventional criteriaHepatitis C virus eradication with direct-acting antiviral improves insulin resistanceThe concept of therapeutic hierarchy for patients with hepatocellular carcinoma: A multicenter cohort studyClaudin-18 expression in oesophagogastric adenocarcinomas: a tissue microarray study of 523 molecularly profiled casesThere is much more to rely on histology than the sole endoscopy tells usA tricky case of pancreatic arteriovenous malformation: the role of endoscopic ultrasound in the diagnosis of this rare conditionPredictors of duodenal ulcer relapse: a 12-month study in untreated patientsDiagnosis of gastric carcinoma in Japan and western countriesReplyMedical and gastroenterological education during the COVID-19 outbreak
P50
Q28088566-08B29DC3-BCE3-40E0-8218-457B1F26E831Q28551586-5409FE57-E7C5-4941-8238-2E3571536F19Q36782625-6C52C223-E6E9-47C6-813D-DCC2FACC70B6Q38182396-35536F11-6BCE-430B-8CCF-58DCEA62CCECQ38210270-7D2C2C5B-2F7C-4449-8377-498C24F7E3BCQ38763789-AE768FD8-3620-413C-8367-135755DC95A8Q38787346-D3DF2A8F-A812-4680-B39B-27530974AA76Q39204902-EC5C728F-D57B-409F-A686-B461D6187BE9Q39240225-3820A1A9-7A96-4C5E-B742-D834104F5773Q40007128-64E94E79-9982-4BFB-B132-E1A3ECFA07C3Q48203129-FA5CA13C-2069-45D2-A1CC-E14E551AA4E6Q48264892-81344261-8AF8-418E-BB48-38F704B722E3Q50087464-3DF9CD77-5C8F-4B05-96B4-3393CB76158EQ52595527-F2C585A5-229A-4182-B919-A9F208A18D50Q52661700-564D10B9-710A-49CC-A5C1-0F0EAD0F7C22Q53058961-92686301-9D15-4943-B841-0CCA2989ECF7Q54217515-157A265C-7638-483B-9D8A-7BFFA32229F3Q58095381-83FF8228-BC53-40D1-BE15-BAF98426C6BBQ58604505-387F0700-0676-4F5A-A1F3-35482E384CBEQ59125292-01D55D0C-2178-4D36-925A-A0579FF5406DQ64054771-8254E555-23B4-4178-8EF3-64E7AF83CD5CQ90611758-1C43BFB5-0FD6-4840-BA3A-254B43EA66C4Q92313740-34505C25-74BD-4E41-8578-47B46920B7D3Q93000833-C20F90D0-4A46-43DE-8D43-CCDBAB7BC749Q93038125-6D337C0A-FB62-4765-9EF7-2F588C6DF00BQ93371973-497BE678-6018-4B77-9202-3D5DCD4093ACQ93647457-6DC71863-3F86-4CF9-91FC-CEC753ECBA62Q93899825-D7EDA6D9-EEF3-4EE6-9F1F-A5160C511268Q95413543-2A565B9A-50B0-4E27-89F1-D4E2841E3976Q96127615-EC60ACFF-D6B6-44E3-91C1-1DFD1EE7D269
P50
description
researcher (ORCID 0000-0002-2944-1374)
@en
name
Fabio Farinati
@en
type
label
Fabio Farinati
@en
prefLabel
Fabio Farinati
@en
P31
P496
0000-0002-2944-1374